Sp-2-propylthio-ATP-α-B and Sp-2-propylthio-ATP-α-B,b-g- dichloromethylene are novel potent and specific agonists of the human P2Y 11 receptor

Biochemical Pharmacology

Volumn 86, Issue 5, 2013, Pages 645-655

  Haas, Michael ^a   Ben Moshe, Idan ^b   Fischer, Bilha ^b   Reiser, Georg ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

AR C67085; ATP; Nucleotide receptor; P2Y receptor; Purinergic agonist

Indexed keywords

2 SPR ADENOSINE 5' O (ALPHA BORANOTRIPHOSPHATE); 2 SPR ADENOSINE 5' O (ALPHA BORANOTRIPHOSPHATE) BETA GAMMA DICHLOROMETHYLENE; 2 SPR ADENOSINE 5' O (ALPHA THIOTRIPHOSPHATE BETA GAMMA DICHLOROMETHYLENE); 2 SPR ADENOSINE 5' O (ALPHA THIOTRIPHOSPHATE); ADENINE NUCLEOTIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; BORANE DERIVATIVE; CYCLIC AMP; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; ASTROCYTOMA CELL; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG POTENCY; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PURIFICATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STABLE TRANSFECTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 84884909361     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.013     Document Type: Article

References (35)

1. Communi D, Govaerts C, Parmentier M, Boeynaems JM. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997;272:31969-73. (Pubitemid 28011862)
2. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysi-ology to therapy. Pharmacol Rev 2006;58:281-341. (Pubitemid 44394905)
3. Hoffmann C, Ziegler N, Reiner S, Krasel C, Lohse MJ. Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2. J Biol Chem 2008;283:30933-41.
4. Berchtold S, Ogilvie AL, Bogdan C, Muhl-Zurbes P, Ogilvie A, Schuler G, et al. Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett 1999;458:424-8. (Pubitemid 29433848)
5. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, et al. Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study.Biochim Biophys Acta 2001;1521: 107-19. (Pubitemid 33020772)
6. Schnurr M, Toy T, Stoitzner P, Cameron P, Shin A, Beecroft T, et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 2003;102:613-20. (Pubitemid 36841983)
7. Wihlborg AK, Balogh J, Wang L, Borna C, Dou Y, Joshi BV, et al. Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ Res 2006;98:970-6.
8. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B. The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol 2001;166:7172-7. (Pubitemid 32525589)
9. Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, et al. NF546 [4,40-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phe- nylene)-car bonylimino))-bis(1,3-xylene-alpha,alpha0-diphosphonic acid) tet-rasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther 2010;332:238-47.
10. Vaughan KR, Stokes L, Prince LR, Marriott HM, Meis S, Kassack MU, et al. Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J Immunol 2007;179:8544-53.
11. Nguyen TD, Meichle S, Kim US, Wong T, Moody MW. P2Y11, a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells. Am J Physiol Gastrointest Liver Physiol 2001;280:G795-804.
12. Communi D, Janssens R, Robaye B, Zeelis N, Boeynaems JM. Rapid up-regula-tion of P2Y messengers during granulocytic differentiation of HL-60 cells. FEBS Lett 2000;475:39-42. (Pubitemid 30331074)
13. Amisten S, Melander O, Wihlborg AK, Berglund G, Erlinge D. Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11. Eur Heart J 2007;28: 13-8. (Pubitemid 46134951)
14. Di Virgilio F, Solini A. P2 receptors: new potential players in atherosclerosis. Br J Pharmacol 2002;135:831-42. (Pubitemid 34214442)
15. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011;43:66-71.
16. Inoue K, Hosoi J, Denda M. Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. J Invest Dermatol 2007;127:362-71. (Pubitemid 46106915)
17. King BF, Townsend-Nicholson A. Involvement of P2Y1 and P2Y11 purinoceptors in parasympathetic inhibition of colonic smooth muscle. J Pharmacol Exp Ther 2008;324:1055-63. (Pubitemid 351397835)
18. Gorini S, Callegari G, Romagnoli G, Mammi C, Mavilio D, Rosano G, et al. ATP secreted by endothelial cells blocks CX3CL 1-elicited natural killer cell che-motaxis and cytotoxicity via P2Y11 receptor activation. Blood 2010;116: 4492-500.
19. Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem 2005;48:7040-8. (Pubitemid 41533126)
20. Communi D, Robaye B, Boeynaems J-M. Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol 1999;128:1199-206.
21. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999;42:213-20. (Pubitemid 29069856)
22. Marteau F, Le Poul E, Communi D, Labouret C, Savi P, Boeynaems JM, et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharma-col 2003;64:104-12. (Pubitemid 36759823)
23. Ecke D, Tulapurkar ME, Nahum V, Fischer B, Reiser G. Opposite diastereose-lective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 50-O- (a-boranotriphosphate) analogues. Br J Pharmacol 2006;149:416-23. (Pubitemid 44582248)
24. Ecke D, Fischer B, Reiser G. Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis. Br J Pharmacol 2008;155:1250-5.
25. Zylberg J, Ecke D, Fischer B, Reiser G. Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochem J 2007;405: 277-86. (Pubitemid 47075163)
26. Eliahu S, Martin-Gil A, Perez de Lara MJ, Pintor J, Camden J, Weisman GA, et al. 2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pres-sure. J Med Chem 2010;53:3305-19.
27. Tulapurkar ME, Laubinger W, Nahum V, Fischer B, Reiser G. Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 50-O-(1-boranotriphosphate) derivatives. Br J Pharmacol 2004;142: 869-78. (Pubitemid 38998100)
28. Tulapurkar ME, Zundorf G, Reiser G. Internalization and desensitization of a green fluorescent protein-tagged P2Y nucleotide receptor are differently controlled by inhibition of calmodulin-dependent protein kinase II. J Neuro-chem 2006;96:624-34.
29. El-Tayeb A, Iqbal J, Behrenswerth A, Romio M, Schneider M, Zimmermann H, et al. Nucleoside-50-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-50-nucleotidase. J Med Chem 2009;52: 7669-77.
30. He K, Hasan A, Krzyzanowska B, Shaw BR. Synthesis and separation of diastereomers of ribonucleoside 50-(alpha-P-Borano)triphosphates. J Org Chem 1998;63:5769-73. (Pubitemid 128491742)
31. Griffin BE, Jarman M, Reese CB, Sulston JE. The synthesis of oligoribonucleo-tides. II. Methoxymethylidene derivatives of ribonucleosides and 50-ribonu-cleotides. Tetrahedron 1967;23:2301-13.
32. Major DT, Fischer B. Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor. J Med Chem 2004;47:4391-404. (Pubitemid 39096828)
33. Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995;16:179-81.
34. Ginsburg-Shmuel T, Haas M, Grbic D, Arguin G, Nadel Y, Gendron FP, et al. UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety. Bioorg Med Chem 2012;20: 5483-95.
35. Nahum V, Tulapurkar M, Levesque SA, Sevigny J, Reiser G, Fischer B. Diade-nosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. J Med Chem 2006;49:1980-90.